Stay updated on T-DM1 Osimertinib Combo for HER2 in NSCLC Clinical Trial
Sign up to get notified when there's something new on the T-DM1 Osimertinib Combo for HER2 in NSCLC Clinical Trial page.

Latest updates to the T-DM1 Osimertinib Combo for HER2 in NSCLC Clinical Trial page
- Check6 days agoChange DetectedA new revision entry v3.4.3 was added to the history, and the previous revision v3.4.2 was removed.SummaryDifference0.1%

- Check13 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check34 days agoChange DetectedA new revision entry (Revision: v3.4.2) was added to the record history, and the notice about government funding lapse as well as the previous revision (v3.4.1) were removed.SummaryDifference0.9%

- Check41 days agoChange DetectedNotice about government funding affecting site operations was added, and the site version was updated to v3.4.1 while v3.4.0 was removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.9%

- Check48 days agoChange DetectedUI changes include showing the glossary, green and red highlights to indicate additions and deletions, and minor revision notes; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference1%

- Check62 days agoChange DetectedStudy Record Versions now show addition of revision v3.3.4 and deletion of revision v3.3.3 as part of routine version history maintenance. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check84 days agoChange DetectedA new revision entry 'Revision: v3.3.3' appears in the Study Record Versions. The footer no longer displays 'HHS Vulnerability Disclosure' and 'Revision: v3.3.2'. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

Stay in the know with updates to T-DM1 Osimertinib Combo for HER2 in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the T-DM1 Osimertinib Combo for HER2 in NSCLC Clinical Trial page.